{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T17:50:06Z","timestamp":1778176206418,"version":"3.51.4"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Opioid-induced constipation (OIC) is one of the most common adverse events of opioid therapy and can severely reduce quality of life (QOL). Naldemedine is the orally available peripheral-acting \u03bc-opioid receptor antagonist approved for OIC treatment. However in daily clinical practice, some cancer patients show insufficient control of OIC even while receiving naldemedine.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Objective<\/jats:title>\n<jats:p>To identify factors associated with non-response to naldemedine in cancer patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This study retrospectively analyzed 127 cancer patients prescribed naldemedine at Seirei Hamamatsu General Hospital in Japan between November 2016 and June 2021. For the regression analysis of factors associated with OIC, variables were extracted manually from electronic medical records. Naldemedine had been prescribed by the attending physician after the presence of OIC had been defined with reference to Rome IV diagnostic criteria. Naldemedine was evaluated as \u201ceffective\u201d in cases where the number of defecations increased at least once in the first 3 days after starting naldemedine. Multivariate logistic regression analysis was performed to identify factors associated with non-response to naldemedine. The data used were from the group of patients who received naldemedine in our previous study.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Results<\/jats:title>\n<jats:p>Factors significantly associated with non-response to naldemedine included chemotherapy with taxanes within 1 month of evaluation of naldemedine effect (odds ratio [OR] = 0.063; 95% confidence interval [CI] = 0.007\u20130.568), and addition of or switching to naldemedine due to insufficient efficacy of prior laxatives (OR = 0.352, 95% CI = 0.129\u20130.966).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The identification of factors associated with non-response to naldemedine prescribed for OIC may help improve QOL among cancer patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0278823","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T18:26:15Z","timestamp":1670610375000},"page":"e0278823","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0095-2293","authenticated-orcid":true,"given":"Yuko","family":"Kanbayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayumi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsushige","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayako","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"key":"pone.0278823.ref001","first-page":"e14386","article-title":"Opioid-Induced Constipation in Advanced Cancer Patients","volume":"13","author":"N.A. Almouaalamy","year":"2021","journal-title":"Cureus"},{"key":"pone.0278823.ref002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/2050640618818305","article-title":"Pathophysiology and management of opioid-induced constipation: European expert consensus statement","volume":"7","author":"AD Farmer","year":"2019","journal-title":"United European Gastroenterol J"},{"key":"pone.0278823.ref003","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1517\/14740338.2015.1041915","article-title":"Opioid risk assessment in palliative medicine","volume":"14","author":"D Krashin","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"pone.0278823.ref004","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1007\/s00520-011-1281-y","article-title":"Emerging drugs for cancer-related pain","volume":"19","author":"S. Mercadante","year":"2011","journal-title":"Support Care Cancer"},{"key":"pone.0278823.ref005","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-017-0750-0","article-title":"Naldemedine: First Global Approval","volume":"77","author":"A. Markham","year":"2017","journal-title":"Drugs"},{"key":"pone.0278823.ref006","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2017.73.0853","article-title":"Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer","volume":"35","author":"N Katakami","year":"2017","journal-title":"J Clin Oncol"},{"key":"pone.0278823.ref007","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S2468-1253(17)30105-X","article-title":"Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials","volume":"2","author":"M Hale","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"pone.0278823.ref008","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.08.018","article-title":"Sultan S; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Technical Review on the Medical Management of Opioid-Induced Constipation","volume":"156","author":"B Hanson","year":"2019","journal-title":"Gastroenterology"},{"key":"pone.0278823.ref009","article-title":"Risk factors for opioid-induced constipation in cancer patients: a single-institution, retrospective analysis","author":"Y Kanbayashi","year":"2022","journal-title":"Support Care Cancer"},{"key":"pone.0278823.ref010","doi-asserted-by":"crossref","first-page":"815156","DOI":"10.3389\/fmed.2022.815156","article-title":"Prevalence and Risk Factors of Functional Constipation According to the Rome Criteria in China: A Systematic Review and Meta-Analysis","volume":"9","author":"Z Chen","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"Suppl 4","key":"pone.0278823.ref011","first-page":"iv111","article-title":"Diagnosis, assessment and management of constipation in advanced cancer","volume":"29","author":"PJ Larkin","year":"2018","journal-title":"ESMO Clinical Practice Guidelines. Ann Oncol"},{"key":"pone.0278823.ref012","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/jnu.12555","article-title":"Nonpharmacological Clinical Effective Interventions in Constipation: A Systematic Review","volume":"52","author":"CFCS Pinto","year":"2020","journal-title":"J Nurs Scholarsh"},{"key":"pone.0278823.ref013","doi-asserted-by":"crossref","first-page":"e968","DOI":"10.1634\/theoncologist.2018-0476","article-title":"Adverse Drug Reactions in an Oncological Population: Prevalence, Predictability, and Preventability","volume":"24","author":"AH Lavan","year":"2019","journal-title":"Oncologist"},{"key":"pone.0278823.ref014","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s11864-022-00976-y","article-title":"Constipation in Cancer Patients\u2014an Update of Clinical Evidence","volume":"23","author":"T Dzier\u017canowski","year":"2022","journal-title":"Curr Treat Options Oncol"},{"key":"pone.0278823.ref015","first-page":"175","article-title":"Factors affecting the effect of naldemedine for opioid-induced constipation: a single-institution, retrospective analysis","volume":"76","author":"Y Kanbayashi","year":"2021","journal-title":"Pharmazie"},{"key":"pone.0278823.ref016","article-title":"Rome IV Diagnostic Questionnaires and Tables for Investigators and Clinicians","author":"OS Palsson","year":"2016","journal-title":"Gastroenterology"},{"key":"pone.0278823.ref017","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2019.12.021","article-title":"Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom","volume":"158","author":"OS Palsson","year":"2020","journal-title":"Gastroenterology"},{"key":"pone.0278823.ref018","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1634\/theoncologist.2018-0590","article-title":"Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer","volume":"24","author":"KA Nyrop","year":"2019","journal-title":"Oncologist"},{"key":"pone.0278823.ref019","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s40261-020-00902-w","article-title":"Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects","volume":"40","author":"K Fukumura","year":"2020","journal-title":"Clin Drug Investig"},{"key":"pone.0278823.ref020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-019-03905-3","article-title":"Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes","volume":"84","author":"M van Eijk","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"pone.0278823.ref021","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejphar.2013.02.058","article-title":"Taxanes: old drugs, new oral formulations","volume":"717","author":"RA Jibodh","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"pone.0278823.ref022","first-page":"e16201","article-title":"Efficacy and Safety of Peripherally Acting \u03bc-Opioid Receptor Antagonist (PAMORAs) for the Management of Patients With Opioid-Induced Constipation: A Systematic Review","volume":"13","author":"M Rekatsina","year":"2021","journal-title":"Cureus"},{"key":"pone.0278823.ref023","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2169\/internalmedicine.3098-19","article-title":"Naldemedine-induced Opioid Withdrawal Syndrome in a Patient with Breast Cancer without Brain Metastasis","volume":"59","author":"K Ishii","year":"2020","journal-title":"Intern Med"},{"key":"pone.0278823.ref024","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/00002018-200326040-00003","article-title":"Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting","volume":"26","author":"AL Kovac","year":"2003","journal-title":"Drug Saf"},{"key":"pone.0278823.ref025","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.gastro.2018.07.016","article-title":"American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation","volume":"156","author":"American Gastroenterological Association Institute Clinical Guidelines Committee","year":"2019","journal-title":"Gastroenterology"},{"key":"pone.0278823.ref026","first-page":"1837","article-title":"Opioid-Induced Constipation and Bowel Dysfunction: A Clinical Guideline","volume":"18","author":"S M\u00fcller-Lissner","year":"2017","journal-title":"Pain Med"},{"key":"pone.0278823.ref027","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1080\/07315724.2020.1727380","article-title":"Risk Factors for Constipation in Adults: A Cross-Sectional Study","volume":"39","author":"G Yurtda\u015f","year":"2020","journal-title":"J Am Coll Nutr"},{"key":"pone.0278823.ref028","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s00520-019-04996-7","article-title":"More opioids, more constipation? Evaluation of longitudinal total oral opioid consumption and self-reported constipation in patients with cancer","volume":"28","author":"EJ Roeland","year":"2020","journal-title":"Support Care Cancer"},{"key":"pone.0278823.ref029","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/23809000.2016.1131595","article-title":"Opioid induced constipation in cancer patients: pathophysiology, diagnosis and treatment","volume":"1","author":"A Rumman","year":"2016","journal-title":"Expert Review of Quality of Life in Cancer Care"},{"key":"pone.0278823.ref030","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/AJP.0000000000000852","article-title":"Opioid-induced Constipation: A Review of Health-related Quality of Life, Patient Burden, Practical Clinical Considerations, and the Impact of Peripherally Acting \u03bc-Opioid Receptor Antagonists","volume":"36","author":"CE Argoff","year":"2020","journal-title":"Clin J Pain"},{"key":"pone.0278823.ref031","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/annonc\/mdy118","article-title":"Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer","volume":"29","author":"N Katakami","year":"2018","journal-title":"Ann Oncol"},{"key":"pone.0278823.ref032","first-page":"CD010270","article-title":"Transdermal fentanyl for cancer pain","volume":"2013","author":"G Hadley","year":"2013","journal-title":"Cochrane Database Syst Rev"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0278823","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T18:26:29Z","timestamp":1670610389000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0278823"}},"subtitle":[],"editor":[{"given":"Masahiko","family":"Sumitani","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":32,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0278823","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,9]]}}}